EMA Withdrawn: Imatinib medac (imatinib) — Medac

View source ↗

Summary

The EMA has withdrawn Imatinib Medac (imatinib) from the market.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dermatofibrosarcoma
• Hypereosinophilic Syndrome
• Leukemia Myelogenous Chronic Bcr-abl Positive
• Myelodysplastic Myeloproliferative Diseases
• Precursor Cell Lymphoblastic Leukemia-lymphoma

Drugs mentioned

• Imatinib Medac (imatinib)

Snippet

Status: Withdrawn. Therapeutic area: Precursor Cell Lymphoblastic Leukemia-Lymphoma;Dermatofibrosarcoma;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Myelodysplastic-Myeloproliferative Diseases;Hypereosinophilic Syndrome. MAH: Medac. Decision date: 11/04/2018